Clinical Research: Clinical Trials

Contributing journals to this collection:
Cancer Prevention Journals Portal, Cancer Prevention Journals Portal Content, , Cancer Reviews Online, Molecular Cancer Research, Cancer Prevention Research, Molecular Cancer Therapeutics, Cancer Research, Cancer Reviews Online Content, Clinical Cancer Research, and Cancer Epidemiology Biomarkers & Prevention

Citations 1-10 of 31 total displayed.

Most recent content

Reviews
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia

Alfonso Quintás-Cardama and Jorge Cortes
Clin. Cancer Res. 2008; 14: 4392-4399. [Abstract] [Full text] [PDF]  

Past content

CCR Focus
Leveraging Exploratory Investigational New Drug Studies to Accelerate Drug Development

David Jacobson-Kram and George Mills
Clin. Cancer Res. 2008; 14: 3670-3674. [Abstract] [Full text] [PDF]  

CCR Focus
Designing Phase 0 Cancer Clinical Trials

Anthony J. Murgo, Shivaani Kummar, Larry Rubinstein, Martin Gutierrez, Jerry Collins, Robert Kinders, Ralph E. Parchment, Jiuping Ji, Seth M. Steinberg, Sherry X. Yang, Melinda Hollingshead, Alice Chen, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski, and James H. Doroshow
Clin. Cancer Res. 2008; 14: 3675-3682. [Abstract] [Full text] [PDF]  

CCR Focus
Phase 0 Trials: An Industry Perspective

Helen Eliopoulos, Vincent Giranda, Robert Carr, Rita Tiehen, Terri Leahy, and Gary Gordon
Clin. Cancer Res. 2008; 14: 3683-3688. [Abstract] [Full text] [PDF]  

CCR Focus
Patient Perspectives on Phase 0 Clinical Trials

Martin Gutierrez and Deborah Collyar
Clin. Cancer Res. 2008; 14: 3689-3691. [Full text] [PDF]  

CCR Focus
The Ethics of Phase 0 Oncology Trials

Emily Abdoler, Holly Taylor, and David Wendler
Clin. Cancer Res. 2008; 14: 3692-3697. [Abstract] [Full text] [PDF]  

Review
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

Jorge A. Garcia and David Danielpour
Mol. Cancer Ther. 2008; 7: 1347-1354. [Abstract] [Full text] [PDF]  

Reviews
Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion

Kelly A. May and Fadlo R. Khuri
Cancer Res. 2008; 68: 4013-4017. [Abstract] [Full text] [PDF]  

Focus Section
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue

Hak Choy, Clinton Park, and Min Yao
Clin. Cancer Res. 2008; 14: 1633-1638. [Abstract] [Full text] [PDF]  

Focus Section
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

Robert Z. Orlowski and Deborah J. Kuhn
Clin. Cancer Res. 2008; 14: 1649-1657. [Abstract] [Full text] [PDF]  

[Next page] Pages: 1 2 3 4